Long non-coding RNA HULC exerts oncogenic activity on papillary thyroid cancer in vitro and in vivo

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Villagelin DG, Santos RB, Romaldini JH. Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis? J Endocrinol Invest. 2011;34(11):e403–e408.
   PubMed Web of Science ®Google Scholar
• Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery. 2010;148(6):1147–1152.
   PubMed Web of Science ®Google Scholar
• Li JY, Shi J, Sang JF, et al. Role of survivin in the pathogenesis of papillary thyroid carcinoma. Genet Mol Res. 2015;14(4):15102–15111.
   PubMed Web of Science ®Google Scholar
• Liebner DA, Shah MH. Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Endocrinol. 2011;2(5):173–195.
   PubMedGoogle Scholar
• Johnsson P, Lipovich L, Grander D, et al. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim Biophys Acta. 2014;1840(3):1063–1071.
   PubMed Web of Science ®Google Scholar
• Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24(3):257–277.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen F, Zhao M, et al. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem. 2017;292(37):15395–15407.
   PubMed Web of Science ®Google Scholar
• Shi F, Xiao F, Ding P, et al. Long noncoding RNA highly up-regulated in liver cancer predicts unfavorable outcome and regulates metastasis by MMPs in triple-negative breast cancer. Arch Med Res. 2016;47(6):446–453.
   PubMed Web of Science ®Google Scholar
• Jin C, Shi W, Wang F, et al. Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget. 2016;7(32):51763–51772.
   PubMedGoogle Scholar
• Yang XJ, Huang CQ, Peng CW, et al. Long noncoding RNA HULC promotes colorectal carcinoma progression through epigenetically repressing NKD2 expression. Gene. 2016;592(1):172–178.
   PubMed Web of Science ®Google Scholar
• Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014;31(12):346.
   PubMed Web of Science ®Google Scholar
• Sun XH, Yang LB, Geng XL, et al. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp Pathol. 2015;8(3):2994–3000.
   PubMed Web of Science ®Google Scholar
• Li SP, Xu HX, Yu Y, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget. 2016;7(27):42431–42446.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma W, Liu Y. Long non-coding RNA HULC promotes bladder cancer cells proliferation but inhibits apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway. Cancer Biomark. 2017;20(4):425–434.
   PubMed Web of Science ®Google Scholar
• Rathinasamy B, Velmurugan BK. Role of lncRNAs in the cancer development and progression and their regulation by various phytochemicals. Biomed Pharmacother. 2018;102:242–248.
   PubMed Web of Science ®Google Scholar
• Yang BF, Cai W, Chen B. LncRNA SNHG12 regulated the proliferation of gastric carcinoma cell BGC-823 by targeting microRNA-199a/b-5p. Eur Rev Med Pharmacol Sci. 2018;22(5):1297–1306.
   PubMed Web of Science ®Google Scholar
• Tang W, Li J, Liu H, et al. MiR-106a promotes tumor growth, migration, and invasion by targeting BCL2L11 in human endometrial adenocarcinoma. Am J Transl Res. 2017;9(11):4984–4993.
   PubMed Web of Science ®Google Scholar
• Luo B, Kang N, Chen Y, et al. Oncogene miR-106a promotes proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro. Minerva Med. 2018;109(1):24–30.
   PubMed Web of Science ®Google Scholar
• Shen CT, Qiu ZL, Song HJ, et al. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(−) symporter in thyroid cancer by regulating MAPK signaling pathway. J Exp Clin Cancer Res. 2016;35(1):101.
   PubMedGoogle Scholar
• Ish-Shalom S, Lichter A. Analysis of fungal gene expression by real time quantitative PCR. Methods Mol Biol. 2010;638:103–114.
   PubMedGoogle Scholar
• Wang Y, Kong D. MicroRNA-136 promotes lipopolysaccharide-induced ATDC5 cell injury and inflammatory cytokine expression by targeting myeloid cell leukemia 1. J Cell Biochem. 2018;119(11):9316–9326.
   PubMed Web of Science ®Google Scholar
• Kong L, Wang X, Zhang K, et al. Gypenosides synergistically enhances the anti-tumor effect of 5-fluorouracil on colorectal cancer in vitro and in vivo: a role for oxidative stress-mediated DNA damage and p53 activation. PLOS One. 2015;10(9):e0137888.
   PubMed Web of Science ®Google Scholar
• Wang X, Xie Y, Wang J. Overexpression of microRNA-34a-5p inhibits proliferation and promotes apoptosis of human cervical cancer cells by downregulation of Bcl-2. Oncol Res. 2018;26(6):977–985.
   PubMed Web of Science ®Google Scholar
• Braconi C, Patel T. Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets. 2012;12(9):1073–1080.
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18.
   PubMed Web of Science ®Google Scholar
• Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017;474(24):4219–4251.
   PubMedGoogle Scholar
• Chen S, Wu DD, Sang XB, et al. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma. Cell Death Dis. 2017;8(10):e3118.
   PubMedGoogle Scholar
• Jendrzejewski J, Thomas A, Liyanarachchi S, et al. PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression. J Clin Endocrinol Metab. 2015;100(10):E1370–E1377.
   PubMed Web of Science ®Google Scholar
• Kim D, Lee WK, Jeong S, et al. Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer. Mol Cell Endocrinol. 2016;431:36–45.
   PubMed Web of Science ®Google Scholar
• Lei H, Gao Y, Xu X. LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin. 2017;49(7):588–597.
   Google Scholar
• Liao D, Lv G, Wang T, et al. Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma. Cancer Cell Int. 2018;18:47.
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Godskesen LE, Jensen MD, et al. Fragments of citrullinated and MMP-degraded vimentin and MMP-degraded type III collagen are novel serological biomarkers to differentiate Crohn’s disease from ulcerative colitis. J Crohns Colitis. 2015;9(10):863–872.
   PubMed Web of Science ®Google Scholar
• Di Gregoli K, George SJ, Jackson CL, et al. Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res. 2016;109(2):318–330.
   PubMed Web of Science ®Google Scholar
• Angrand PO, Vennin C, Le Bourhis X, et al. The role of long non-coding RNAs in genome formatting and expression. Front Genet. 2015;6:165.
   PubMed Web of Science ®Google Scholar
• Shumayla Sharma S, Taneja M, et al. Survey of high throughput RNA-Seq data reveals potential roles for lncRNAs during development and stress response in bread wheat. Front Plant Sci. 2017;8:1019.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhao Y, Yang S, et al. An integrated analysis of miRNA, lncRNA, and mRNA expression profiles. BioMed Res Int. 2014;2014:345605.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.
   PubMed Web of Science ®Google Scholar
• Xu Y, Han YF, Zhu SJ, et al. miRNA148a inhibits cell growth of papillary thyroid cancer through STAT3 and PI3K/AKT signaling pathways. Oncol Rep. 2017;38(5):3085–3093.
   PubMed Web of Science ®Google Scholar
• Chou CK, Liu RT, Kang HY. MicroRNA-146b: a novel biomarker and therapeutic target for human papillary thyroid cancer. Int J Mol Sci. 2017;18(3):636.
   PubMed Web of Science ®Google Scholar
• Minna E, Romeo P, Dugo M, et al. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Oncotarget. 2016;7(11):12731–12747.
   PubMedGoogle Scholar
• Geraldo MV, Nakaya HI, Kimura ET. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Oncotarget. 2017;8(6):9597–9607.
   PubMed Web of Science ®Google Scholar
• Matson DR, Hardin H, Buehler D, et al. AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion. Exp Mol Pathol. 2017;103(3):288–293.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Liu Y, Ma M, et al. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/beta-catenin signaling pathway. Biomed Pharmacother. 2017;96:98–103.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang X, Qi L, et al. HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget. 2016;7(12):14429–14440.
   PubMedGoogle Scholar
• Zhou Z, Shu B, Xu Y, et al. microRNA-203 modulates wound healing and scar formation via suppressing HES1 expression in epidermal stem cells. Cell Physiol Biochem. 2018;49(6):2333–2347.
   PubMedGoogle Scholar